- Hyphens Pharma (SGX:1J5) 2H2023 has demonstrated remarkable growth in 2H23 vis-à-vis just half year before in 1H23. Revenue up 28.4% h-h to S$95.9m, leading to 2H23 net profit improving by 43.4% h-h to S$5.1m.
- - Read this at SGinvestors.io -
Medical Aesthetics Arm.
- Hyphens Pharma’s acquisition of Ardence Pharma and the establishment of Ardence Aesthetics in Singapore marks significant milestones for Hyphens. This strategic move solidifies the company’s presence in Singapore and Malaysia and adds an exciting range of products to the medical aesthetic business.
- - Read this at SGinvestors.io -
7-11 collaboration.
- In a bid to enhance market visibility and penetration, Hyphens Pharma has partnered with 7-Eleven to offer Ocean Health supplements at 112 convenience stores in Singapore. This strategic collaboration is set to bolster the brand’s reach and deliver long-term growth for the Company.
Middle East market.
- Read more at SGinvestors.io.
Daniel Ng SAC Capital Research | Matthias Chan SAC Capital | https://www.saccapital.com.sg/ 2024-03-26
Previous report by SAC:
2023-11-20 Hyphens Pharma International - 3Q23 Business Update.
Price targets by 2 other brokers at Hyphens Pharma Target Prices.
Listing of research reports at Hyphens Pharma Analyst Reports.
Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corporate Actions,
Hyphens Pharma News Articles
